Señales en vivo de NWRN.SW | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 may 2024 @ 11:19):

Stats
Volumen de hoy	402 143
Volumen promedio	80 092.00
Capitalización de mercado	186.32M
EPS	CHF0 ( 2024-03-14 )
Last Dividend	CHF0 ( N/A )
Next Dividend	CHF0 ( N/A )
P/E	-11.24
ATR14	CHF0.0310 (0.31%)

Volumen Correlación

Largo: 0.05 (neutral)

Corto: 0.82 (strong)

Signal:(47.602) Same movement expected

Newron Pharmaceuticals Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Newron Pharmaceuticals Correlación - Moneda/Commodity

0.58
( weak )

0.21
( neutral )

0.00
( neutral )

0.21
( neutral )

0.13
( neutral )

-0.24
( neutral )

Newron Pharmaceuticals Finanzas

Annual	2023
Ingresos:	CHF9.06M
Beneficio Bruto:	CHF9.06M (100.00 %)
EPS:	CHF-0.910

FY	2023
Ingresos:	CHF9.06M
Beneficio Bruto:	CHF9.06M (100.00 %)
EPS:	CHF-0.910

FY	2022
Ingresos:	CHF6.09M
Beneficio Bruto:	CHF6.09M (100.00 %)
EPS:	CHF-0.980

FY	2021
Ingresos:	CHF5.76M
Beneficio Bruto:	CHF0.00 (0.00 %)
EPS:	CHF-0.840

Financial Reports:

No articles found.

Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease, as well as develops Xadago for the treatment of levodopa induced dyskinesia. It also develops Evenamide for Schizophrenia and treatment resistant schizophrenia; and Ralfinamide for orphan indication in neuropathic pain. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.